Novo Still Has Work to Do to Build Investor Confidence, CEO Says

Novo CEO Mike Doustdar told Bloomberg Television that the company is examining external partnerships to address gaps in its drug portfolio. Doustdar stated the company does not rely solely on internal development and is open to outside solutions for strategic and scientific needs. Bloomberg reported Doustdar also discussed investor confidence and the company's obesity drug offerings during the interview.

Next story